NEW YORK (360Dx) – Oxford Immunotec on Sunday said that its board has approved a share repurchase program of up to $100 million of the company's outstanding ordinary shares over a five-year period.

The program will be presented for shareholder approval on or before the company's annual general shareholder meeting on June 18.